• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Neoplasia (New York, N.Y.)

    Neoplasia (New York, N.Y.)

    JournalISSN 1522-8002eISSN 1476-5586中科院 医学 2区

    年发文量

    研究主题

    论文(2949)

    排序
    1Co-mutation Of
    Muhammad Adnan,Laura Libera,Antonio Travaglino,Nora Sahnane,Sofia Facchi, Giorgia Ortelli, Anna Giudici, Tommaso Meschini, Simona De Toffol, Denis Cominetti, Jvan Casarin,Stefano La Rosa,

    Objective: The interaction between oncogenic signalling and epigenetics in endometrioid endometrial carcinoma (EEC) is poorly defined. We investigated the potential association of KRAS-ARID1A co-mutation axis with a distinct hypermethylator phenotype, affecting focal MLH1 promoter methylation and global DNA methylation (LINE-1). Methods: We analysed an institutional cohort of 83 EECs and a public dataset of 1300 cases (cBioPortal). Molecular profiling included Next-Generation Sequencing (NGS) for KRAS and ARID1A mutations, MS-MLPA for MLH1 promoter methylation, and pyrosequencing for global LINE-1 methylation levels. Results: In large-scale dataset, KRAS mutations significantly associated with MSI ( p = 0.003 ) and MLH1 hypermethylation ( p = 0.0001 ). In our cohort, KRAS -mutated tumours exhibited significantly higher LINE-1 methylation than wild-type cases ( p = 0.0079 ). ARID1A mutations co-occurred in 76% of KRAS -mutated cases in our cohort, consistent with significant co-occurrence observed in cBioPortal dataset ( p = 0.001 ). This dual-mutant KRAS-ARID1A subset defined a distinctive epigenetic signature characterised by the highest global DNA methylation levels ( p = 0.0474 ) and an increased incidence of sporadic mismatch repair deficiency. Multivariable logistic regression demonstrated that this co-mutation pattern remained significant independently of established molecular subtypes of EC. Exploratory survival analyses suggested improved OS in ARID1A -mutated tumours ( p = 0.0188 ) whereas KRAS -mutated tumours showed a trend towards longer DFS ( p = 0.0594 ). Conclusions: The KRAS-ARID1A co-mutation identifies a distinct molecular subset of EEC mainly characterised by sporadic mismatch repair deficiency and global hypermethylation. Moreover, these findings suggest that integrating KRAS/ARID1A status and LINE-1 methylation assessment represents a promising hypothesis that warrants further validation as a tool to subclassify the heterogeneous No Specific Molecular Profile (NSMP) group in independent cohorts.

    2027
    引用
    AI阅读
    加入学术空间
    2Epitranscriptomic Regulation Contributes to Multiple Myeloma Biology and Offers Potential Therapeutic Targets
    Amr Ali Mohamed Abdelgawwad El-Sehrawy, Saja Khalil Ibrahim, Sarmad S. Abdullah,Ahmed Hjazi,Priya Priyadarshini Nayak,Navin Kumar Tailor,Aseel Smerat, Salamn M. Abd, Tina Saeed Basunduwah,Chou-Yi Hsu

    RNA modifications are being investigated as contributors to multiple myeloma (MM) biology alongside genomic lesions and bone marrow interactions. This narrative review examines N⁶-methyladenosine (m⁶A), 5-methylcytosine (m⁵C), adenosine-to-inosine editing, and pseudouridylation, with emphasis on the distinction between MM-specific findings and mechanisms proposed from other systems. Functional studies in MM cells and animal models link METTL3, WTAP, FTO, ALKBH5, and YTHDF2 to selected growth, metabolic, and treatment-response programs. Adenosine deaminase acting on RNA 1 (ADAR1) has been implicated in GLI1 editing and regulation of double-stranded RNA sensing during lenalidomide exposure. Patient expression and outcome associations support clinical relevance but do not establish that these regulators determine disease behavior. Evidence for m⁵C is more limited, including an NSUN2–exosomal MALAT1 mechanism in myeloma bone disease, while the pseudouridylation studies discussed here largely concern non-myeloma cancers. Stage-specific regulatory changes across precursor disease and relapse remain hypotheses requiring longitudinal testing. Therapeutic approaches include enzyme inhibition, targeted protein degradation, and RNA-directed strategies; most remain preclinical, and several have been evaluated mainly outside MM. Plasma cell-free RNA studies provide early diagnostic observations, but modification-aware liquid biopsy has not been clinically validated for MM risk stratification, treatment selection, or relapse prediction. Progress will depend on disease-specific target validation, selective delivery, assessment of normal hematopoietic effects, and prospective clinical studies. Epitranscriptomic regulation therefore offers a useful research framework for understanding and potentially targeting MM, without displacing the established contribution of genomic and clinical risk factors.

    2027
    引用
    AI阅读
    加入学术空间
    3Treatment-associated Remodeling of a Mitochondrial Translation-Related Gene Set in Paired Pretreatment and Residual Triple-Negative Breast Tumors
    Xiaoyuan Weng, Yanqi Tang, Qianqian Li, Xiyin Huang, Jinsheng Wang,Jianqing Lin

    Background Longitudinal transcriptional remodeling can reveal treatment-associated tumor states. We examined how a fixed 117-gene nuclear-encoded mitochondrial-translation-related set (MT117) changes across treatment in triple-negative breast cancer (TNBC) and whether its change is isolated or accompanied by other transcriptional programs. Methods We analyzed five public longitudinal datasets. The primary analysis used 19 paired pretreatment and residual TNBC tumors from GSE260693. External or auxiliary analyses used six strict TNBC and 27 all-subtype pairs from GSE240671, seven TNBC pairs from GSE43816, malignant-cell pseudobulk from GSE246613, and chemotherapy-persistent PDX/cell-line systems from GSE164715. Patients or model systems were the inferential units. Results MT117 decreased in GSE260693 (mean paired change, -0.754; 95% CI, -1.051 to -0.456; paired t P = 4.68 × 10^-5), with decreases in 18 of 19 patients, alongside decreases in multiple contextual programs. In GSE240671, the TNBC-minus-non-TNBC difference was 0.099 (95% CI, -0.247 to 0.445; P = 0.575), providing no evidence of TNBC specificity. In the distinct pembrolizumab-plus-radiotherapy GSE246613 cohort, 11 of 13 malignant-cell pairs decreased (mean, -0.131; 95% CI, -0.267 to 0.004; P = 0.0567), but matched-module and covariate-adjusted analyses did not establish pathway-specific independence. Both external paired TNBC cohorts had confidence intervals crossing zero, and only one of four persistent experimental systems followed the primary human direction. Conclusions MT117 is best interpreted as an annotation-defined treatment-associated transcriptional signal that co-occurs with other transcriptional changes. Mitochondrial protein synthesis was not directly measured. The findings do not establish selective mitochondrial-translation inhibition, TNBC specificity, a universal persistence mechanism, or a validated biomarker.

    2027
    引用
    AI阅读
    加入学术空间
    4The Landscape of Nanotechnology in Esophageal Squamous Cell Carcinoma Treatment
    Rui Wang, Xu Han

    Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive and lethal malignancies worldwide, particularly in Asia and Africa, with a 5-year survival rate below 20%. Conventional treatments—surgery, chemotherapy, and radiotherapy—are limited by late-stage diagnosis, systemic toxicity, drug resistance, and poor prognosis. Nanoparticle-based delivery systems have been investigated as a strategy to address these limitations. This structured critical review synthesizes ESCC-specific and supporting evidence on nanotechnology in ESCC treatment. We examine major nanoplatforms—liposomes, albumin-bound nanoparticles, polymeric nanoparticles, metallic nanoparticles, dendrimers, and quantum dots—and their applications in chemotherapy, radiotherapy, nucleic-acid delivery, immunotherapy, and theranostics. Evidence is explicitly graded as ESCC clinical, ESCC in vivo/PDX, ESCC in vitro, other tumor model (supporting evidence only), or conceptual. We discuss the heterogeneity of the enhanced permeability and retention (EPR) effect in ESCC, the gap between preclinical promise and clinical utility, toxicity considerations, green-synthesized nanoparticles, and barriers to translation. By distinguishing established ESCC evidence from supporting and conceptual evidence, this review aims to inform future translational research rather than to claim clinical maturity.

    2027
    引用
    AI阅读
    加入学术空间
    5LncRNA Signatures Associated with Exhausted CD8⁺T Cells for Assessing the Immune Microenvironment and Drug Sensitivity in Pancreatic Adenocarcinoma
    Jiahui Feng, YuTing Mo, Dezhong Yan, Jie Cheng, Lei Peng

    Objectives Pancreatic adenocarcinoma (PAAD) is an aggressive malignancy with generally poor prognosis characterized by significant immune evasion driven primarily by its immunosuppressive tumor microenvironment (TME). A central mechanism underlying this evasion is T cell exhaustion (Tex), particularly in CD8⁺T cells, which limits effective anti-tumor immune responses. This study aimed to identify exhausted CD8⁺T cell-related long non-coding RNAs (CD8TexRLs) and evaluate their clinical relevance, with a focus on constructing a prognostic model, assessing immune microenvironment features, and identifying functionally important lncRNA candidates. Basic Methods To elucidate underlying mechanisms and therapeutic implications, comprehensive analyses covering pathway enrichment, TMB, immune landscape profiling, and drug response prediction were conducted. PAAD samples were further stratified into distinct molecular subtypes using ConsensusClusterPlus. Tumor clonogenic assays and subcutaneous tumor modeling were employed to investigate the impact of AC053503.1 overexpression and knockdown in CD8⁺T cell models on PAAD cell proliferation. Immunohistochemistry revealed that AC053503.1 knockdown in CD8⁺T cells significantly enhanced the tumor proliferation rate. Main Results Seven signature CD8TexRLs—AL162424.1, MIR3142HG, LINC02004, AC053503.1, FLRT1, AC068580.2, and AP005233.2—were identified and integrated into a prognostic model that divided patients into high- and low-risk groups. High-risk individuals displayed pronounced enrichment of B-cell receptor signaling and cytosolic DNA-sensing pathways, together with increased TMB and an altered immune landscape. The model also identified differences in immune features and predicted drug sensitivity between risk groups. Stratification into molecular subtypes further demonstrated distinct immune profiles and predicted therapeutic sensitivities. Functional validation revealed that lncRNA AC053503.1 acts as a tumor suppressor in PAAD, with its knockdown promoting tumor proliferation. Conclusions In summary, our research delineates the complex role of exhausted CD8⁺T cells within the PAAD tumor microenvironment and establishes CD8TexRLs as promising biomarkers for predicting both immunotherapy responses and patient survival. Particularly, functional characterization confirmed lncRNA AC053503.1 as a suppressor of PAAD proliferation, revealing new avenues for targeted therapeutic development.

    2027
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2949 篇论文

    高被引作者

    作者引用发文
    Sooryanarayana Varambally1266916
    Arul M. Chinnaiyan1118939
    Darshan Shimoga Chandrashekar91225
    Debashis Ghosh67866
    Shanker Kalyana-Sundaram66135
    Daniel R. Rhodes65864
    Varambally Radhika65293
    Chad Creighton64476
    Balabhadrapatruni V.S.K. Chakravarthi64184
    Sai Akshaya Hodigere Balasubramanya63242

    高产作者

    作者引用发文
    Arul M. Chinnaiyan1118939
    Alnawaz Rehemtulla143828
    Ken Pienta344425
    Ralph Weissleder232424
    Zaver M. Bhujwalla131721
    Yusuke Nakamura148419
    Chinthalapally V. Rao24517
    Mark Rubin239617
    Sooryanarayana Varambally1266916
    Mohammed Altaf23815

    相关期刊

    Oncology research
    Cancer and Metastasis Reviews
    Cancer gene therapy
    Molecular cancer therapeutics
    Oncotarget
    Cancer Immunology Research
    Molecular Cancer Research
    Biomarker Research
    Cellular Oncology
    Molecular Therapy - Oncolytics